Conversely, the novel antidiabetic agents provide substantial advantages; for example, some SGLT-2 inhibitors and GLP-1 RAs may be of particular benefit to patients with type 2 diabetes due to their propensity to cause weight loss and provide cardiovascular benefits [8–11]. Here, GLP1R is linked to type 2 diabetes mellitus.